Key Takeaways
- Eli Lilly's GLP-1 drug, Mounjaro, achieved $8.1B in Q2 revenue, becoming the world's best-selling drug.
- Counterfeit GLP-1s and high US out-of-pocket costs pose market challenges for these drugs.
- Eli Lilly commits $14.2 billion to R&D, defending drug pricing to fund future innovations.
- GLP-1 drugs are showing unexpected potential in treating addiction, mental health, and dementia risk.
- Biotech VC funding declined from $20B to $5B due to AI competition and 'patent hacking'.
Deep Dive
- Eli Lilly's market capitalization has increased 860% under CEO Dave Ricks, driven by innovations like GLP-1s.
- The company's GLP-1 journey began with a diabetes injection in 2006, leading to terzepatide (Mounjaro) discovery in 2014.
- An early 2016 study for terzepatide in healthy volunteers was halted due to participants losing too much weight too quickly.
- Mounjaro is now the best-selling drug globally, generating $8.1 billion in Q2 revenue, an 80% growth.
- Approximately 20 million people globally use prescription GLP-1s, with an unknown number using non-prescription versions.
- Eli Lilly has reduced GLP-1 out-of-pocket costs for some patients from $1,000 to $4.99, with further reductions planned.
- The company defends its drug pricing strategy, citing a significant $14.2 billion investment in R&D this year.
- Drastically cutting prices could stifle R&D and reduce incentives for developing new medicines.
- The guest questioned why anti-obesity drugs are not reimbursed similarly to anti-hypertensive drugs or less effective surgeries.
- Biotech venture capital funding has significantly declined from a peak of $20 billion annually to approximately $5 billion.
- This downturn is attributed to increased competition from AI, an oversaturation of IPOs, and China's 'patent hacking' strategies.
- Eli Lilly prioritizes reinvesting profits into R&D for future breakthroughs, employing 4,200 PhD scientists.
- Eli Lilly's R&D focus includes organic research, building domestic supply chains for injectables, and acquiring external innovation.
- GLP-1 drugs show potential applications beyond weight loss, including addressing addiction and mental health challenges.
- Further research explores their possible use cases in reducing dementia risk, offering new therapeutic avenues.
- These evolving pharmaceutical developments are contrasted with general biohacking approaches to health.
- Pharmaceutical advertising regulations, originating from 1992 print ad rules, lead to often ineffective TV commercials.
- Despite perceived poor quality, these ads demonstrably increase drug demand.
- AI tools like ChatGPT are empowering patients to research healthcare decisions, enhancing information access.
- The guest utilizes AI for research, finding it largely accurate and an effective auditing tool for drug information.
- The conversation addressed proposed cuts to the National Institutes of Health (NIH) budget, questioning their impact on the therapeutic pipeline.
- Concerns were raised regarding potential inefficiencies and influence within the existing NIH grant system.
- Pharmacy Benefit Managers (PBMs), initially for claims processing and bulk drug discounts, are now widely criticized for self-serving practices.